Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals by Katsel, Pavel et al.
Gain in Brain Immunity in the Oldest-Old Differentiates
Cognitively Normal from Demented Individuals
Pavel Katsel
1*, Weilun Tan
1, Vahram Haroutunian
1,2
1Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, United States of America, 2Department of Psychiatry, James J. Peters VA Medical
Center, Bronx, New York, United States of America
Abstract
Background: Recent findings suggest that Alzheimer’s disease (AD) neuropathological features (neuritic plaques and NFTs)
are not strongly associated with dementia in extreme old (over 90 years of age) and compel a search for neurobiological
indices of dementia in this rapidly growing segment of the elderly population. We sought to characterize transcriptional and
protein profiles of dementia in the oldest-old.
Methods and Findings: Gene and protein expression changes relative to non-demented age-matched controls were
assessed by two microarray platforms, qPCR and Western blot in different regions of the brains of oldest-old and younger
old persons who died at mild or severe stages of dementia. Our results indicate that: i) consistent with recent
neuropathological findings, gene expression changes associated with cognitive impairment in oldest-old persons are
distinct from those in cognitively impaired youngest-old persons; ii) transcripts affected in young-old subjects with
dementia participate in biological pathways related to synaptic function and neurotransmission while transcripts affected in
oldest-old subjects with dementia are associated with immune/inflammatory function; iii) upregulation of immune response
genes in cognitively intact oldest-old subjects and their subsequent downregulation in dementia suggests a potential
protective role of the brain immune-associated system against dementia in the oldest-old; iv) consistent with gene
expression profiles, protein expression of several selected genes associated with the inflammatory/immune system in
inferior temporal cortex is significantly increased in cognitively intact oldest-old persons relative to cognitively intact young-
old persons, but impaired in cognitively compromised oldest-old persons relative to cognitively intact oldest-old controls.
Conclusions: These results suggest that disruption of the robust immune homeostasis that is characteristic of oldest-old
individuals who avoided dementia may be directly associated with dementia in the oldest-old and contrast with the
synaptic and neurotransmitter system failures that typify dementia in younger old persons.
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Introduction
The continued expansion of the elderly population resulting
from recent advances in medical treatment, improved nutrition
and reduced birth rate accompanied by elevated age-related risk of
brain disorders such as dementia and Alzheimer’s disease (AD)
have prompted considerable interest in the study of the aging
human brain. These advances in life expectancy have not only led
to an increase in the proportion of the population that is aged, but
also in the numbers of persons who can be classified as the oldest-
old, variably defined as persons over the age of 85 or 90. US
Census Bureau data and projections [1,2] show that the number of
American over the age of 85 (4.4 million in 2001) will rise
significantly by 2010 to 5.8 million and will quadruple to 19.3
million by 2050.
The high frequency of dementia incidence in the elderly with
reported doubling every five years from ages 65 to 85 [3] would
predict that some aspect of dementia will afflict most individuals by
age of 100 [4,5]. However, clinical and neuropathological studies
suggested a decline or plateau in the incidence of dementia in the
oldest-old [6–11]. Moreover, epidemiological studies indicate that
the rate of increase in dementia prevalence falls in octogenarians
and levels off at about 40% at age 95 [9] suggesting a selective
survival effect [12]. These data and socio-demographic studies of
nonagenarians and centenarians (rev. by Imhof et al [13]) support
the possibility that oldest-old persons may represent a select group
with a decreased rate of aging and increased resistance to
biological and physiological stresses and age-related diseases, such
as cancer, stroke and cardiovascular disease. However, even if the
rate of dementia stabilizes beyond age 85, the numbers of oldest-
old persons with dementia are likely to rise to 8–10 million by
2050.
Neuropathological studies laid the foundation for our under-
standing of the development of the dementing processes in AD and
helped define the relationship between neuropathological lesion
severity and the magnitude of cognitive impairment. Neuritic
plaques (NPs) and neurofibrillary tangles (NFTs), as well as
synaptic loss in the temporal neocortex, the entorhinal cortex and
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cognitive deficits in younger AD patients [14–16]. In contrast to
younger cases, persons in their 60s–80s, the relatively limited
number of studies in nonagenarians and centenarians have found
considerable differences in the magnitude and regional/sub-
regional distribution of NPs and NFTs in cognitively impaired
cases [17–20] (but see [21] for contrasting findings). Additionally,
there was no association between AD neuropathology and
neuronal loss in CA1-3 areas of hippocampus (HIPP) and
entorhinal cortex in oldest-old AD cases [22–24]. Moreover,
quantitative studies have found that the neuropathological
correlates of cognitive impairment in AD appear to be more
variable and often significantly less profound in the oldest-old than
in younger persons [17–19,22–29]. The observed reduced NP and
NFT densities in oldest-old individuals diagnosed clinically with
AD raises the question of whether different underlying neurobi-
ological mechanisms are associated with cognitive impairment in
oldest-old persons as compared to younger old persons with
dementia.
Significant progress has been made in understanding the
molecular biological abnormalities in the brains of persons with
AD [30–33]. Despite the substantial interest in transcriptional
abnormalities in AD, most studies have approached abnormal
gene expression in AD by examining gene expression profiles in
groups selected on the basis of specific neuropathology or
cognitively distinct stages of the disease rather than stratifying
demented individuals according to their age. A few studies have
assessed gene expression in the brain throughout the lifespan (13–
106 y.o.) and have shown that significant changes in co-regulated
sets of genes implicated in aging occur early in adult life and
continue progressively during aging [34–36]. The expression of
genes that play a role in synaptic plasticity, vesicular/protein
transport, neurotransmitter release are generally reduced in the
aged cerebral cortex, whereas the expression of genes associated
with the stress responses, DNA damage and repair and immune/
inflammation are frequently increased [34]. A recent study of
cognitively intact non-AD persons that compared gene expression
profiles in the three most vulnerable regions of the AD brain:
HIPP, entorhinal and superior temporal cortex as well as less
vulnerable – postcentral gyrus - across the lifespan (22–99 y.o.) also
showed increased immune activation around the sixth to seventh
decades [35]. The expression of similar categories of genes related
to synaptic function, DNA damage and inflammation with similar
directional changes were also identified in several cortical areas
and the hippocampus of elderly persons diagnosed with AD or
mild cognitive impairment [37–40].
The growing body of evidence showing dissociation between the
neuropathological indices of AD from dementia in the extreme
elderly prompted the current study of the molecular biological
substrates of dementia in this rapidly growing segment of the elderly
population. The presence, absence and severity of dementia was
assessed by the clinical dementia rating (CDR) rating scale [41].
Gene and protein expression profiles of multiple brain regions from
autopsied cognitively normal (CDR0), mildly cognitively impaired
(CDRs 0.5–1) and severe dementia persons (CDRs 4–5) with ages
ranging between 60 and 86 years, were compared to the profiles of
similar groups of oldest-old individuals rangingfrom 87 to 107 years
of age. These cases included persons who evidenced either no
significant neuropathology or only NP and NFT neuropathology.
Cases with clinical conditions known to be associated with cognitive
impairment other than AD (e.g., schizophrenia, major depression)
and cases with neuropathologies associated with conditions other
than AD (e.g. Lewy bodies with or without NPs and NFTs), or
significant cerebrovascular lesions, were excluded.
Results
Median age split groups of cognitively impaired patients
showed different sets of affected genes
All samples in the microarray dataset were divided in two major
age categories based on the median age (87 y.o.) of all of the
subjects: youngest-old (YO; #86 y.o.) and oldest-old (OO;
$87y.o.) in order to analyze gene expression changes in clinically
and neuropathologically distinct age groups of cognitively
impaired subjects and controls (Table 1). In order to identify
genes affected in cognitively impaired individuals and to test
whether similar genes or pathways are affected during the course
of dementia in each age group CDR classified cognitively
impaired subjects were sorted into two additional groups: mild
dementia (MD, CDRs 0.5–1) and severe dementia (SD, CDRs 4–
5). Each of these groups was then compared to age- matched
cognitively normal controls within their respective age categories.
Filtering conditions were: fold change .1.3 and p,0.05; present
call .70%. As shown in Fig. 1, samples from YO and OO MD
groups had significantly smaller number (4 to 8 times) of
differentially expressed probe sets as compared to SD groups
(probe sets are defined as probes on the microarray that identify a
single mRNA transcript). The number of common probe sets
between MD groups in the two age categories, however, were
strikingly small (below 7%) as compared to the overlap between
mildly and severely demented groups within each age category:
48% for YO and 66% for OO individuals, indicating very little
similarity between mildly cognitively impaired persons in the two
age groups. As dementia progressed to terminal stages, this overlap
between the two age groups remained low: approximately 28%.
Removing subjects with questionable dementia (CDR0.5) from the
MD groups did not significantly affect the overall total number of
affected genes in each age group nor the overlapping probe sets,
and even strengthened the percent-wise separation between the
two age cohorts (data not shown).
Pathway analysis showed distinct molecular profiles in
two cognitively impaired cohorts stratified by age
The Ingenuity Pathway Analysis algorithm was used to
determine which signaling pathways were affected in the groups
of cognitively impaired subjects in each of the two age cohorts
(Tables 2 and 3). As expected from the previous analysis (Venn
Fig. 1) that indicated very little overlap between the two age
cohorts of cognitively impaired groups of subjects, there were only
three common pathways observed. The granulocyte/macrophage
colony-stimulating factor (GM-CSF) signaling pathway (related to
innate immune response) appeared among the top scored
pathways in individuals with mild dementia of both age groups.
Oxidative phosphorylation and synaptic LTP were the other two
common pathways significantly affected in individuals with severe
dementia in the two age categories. Additionally, there was a high
level of consistency within the youngest-old cognitively impaired
groups of subjects. Overall, dementia-associated genes with altered
expression in the young-old (Table 2) were predominantly
represented by the signaling, but not by the metabolic, pathways
typically associated with synaptic function, such as GABA and
glutamate receptor signaling, synaptic long term potentiation
(LTP), and pathways associated with neural development,
including neuregulin, IGF1, VEGF, PDGF, PI3K/Akt, axonal
guidance and calcium signaling. Other identified pathways were
previously implicated in brain aging or neurodegenerative
disorders and included IGF1, NF-kB, chemokine, cell cycle, nitric
oxide, NRF2-mediated oxidative stress response and glucocorti-
coid receptor signaling and pathways related to neurodegeneration
Brain Immunity and Dementia
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lateral sclerosis signaling. Generally, broad diversity of listed
signaling pathways in subjects with mild dementia was narrowed,
while percentage of the affected genes relative to the total number
of genes in these pathways was increased in severe cognitively
impaired young-old subjects.
Clear distinctions were observed in the oldest-old cohort with
mild dementia. Changes in the expression of signaling pathways
related to neural function as seen in the young-old subjects
(Table 3) were absent. The majority of the pathways in this group
were related to the innate immune response pathways and
immune function, which were predominantly downregulated.
Only three canonical pathways remained in the cognitively
impaired oldest-old subjects. These pathways were; oxidative
phosphorylation, antigen presentation and synaptic LTP.
Cognitively intact oldest-old subjects showed increased
expression of immune response genes relative to
cognitively intact youngest-old
Because of the clear distinction in genes and pathways
associated with cognitive impairment in young-old and oldest-
old individuals, we sought to determine whether the gene
expression profiles of cognitively intact oldest-old persons were
also different from those of young-old cognitively intact persons.
We compared cognitively intact young-old individuals to cogni-
tively intact oldest-old persons. Under the same filtering conditions
as for the cognitively impaired groups 332 probe sets showed
significantly altered expression in oldest-old cognitively intact
subjects relative to cognitively intact young-old persons. As shown
in Fig. 2, 65 of these 332 ‘‘age-associated’’ probe sets were also
differentially expressed in cognitively impaired young-old persons
and 75 of the 332 probe sets were differentially expressed in
cognitively impaired oldest-old persons. Strikingly, every single
transcript among these common genes, i.e. genes whose expression
was changed as a function of aging (cognitively intact young-old vs.
cognitively intact oldest-old) and as a function of dementia
(cognitively intact vs., cognitively impaired) was changed in the
opposite direction in the cognitively impaired oldest-old subjects
vs. young-old persons. Interferon-induced protein with tetratrico-
Table 1. Sample characteristics.
Dementia Groups/arrays CNT 862 MD 862 SD 862 CNT 87+ MD 87+ SD 87+
Subjects # 15 6 13 7 15 15
Total samples/arrays 144 52 106 72 143 69
Sex (M/F) 7/8 2/4 4/9 1/6 3/12 3/12
Age (years) 75.268.6 76.868.4 80.867.1 94.264.6 90.863.9 92.964.8
Brain pH 6.5560.25 6.3460.09 6.4160.28 6.4960.26 6.3560.28 6.3460.22
PMI (h) 8.6866.18 461.2 5.3165.26 4.0361.53 5.4565.28 3.5561.40
Dementia Groups/qPCR CNT 862 MD 862 SD 862 CNT 87+ MD 87+ SD 87+
Total subjects (N) 7 7 5 6 13 17
Sex (M/F) 2/5 3/4 3/2 3/3 3/10 1/16
Age (years) 77.365.7 77.466.5 79.269.7 89.862.9 90.563.5 92.964.4
Brain pH 6.2960.32 6.3460.25 6.2660.45 6.2760.37 6.3360.24 6.3560.30
PMI (h) 8. 766.2 3.561.2 8.368.8 4.160.1 4.261.9 4.763
Dementia Groups/WB CNT 862 MD 862 SD 862 CNT 87+ MD 87+ SD 87+
Total subjects (N) 10 - 9 10 - 10
Sex (M/F) 4/6 - 3/6 3/7 - 3/7
Age (years) 79.766.7 - 79.067.6 93.264.8 - 93.864.7
Brain pH 6.4360.41 - 6.3860.14 6.560.24 - 6.3560.30
PMI (h) 7.364.6 - 5.264.9 4.261.5 - 4.463.6
{Microarrays were performed in 15 brain regions (BAs: 8, 10, 44, 46, 4, 32/24, 23/31, 20, 21, 22, 36/28, 38, 7, 17 and HIPP). qPCR and western blotting (WB) studies were
performed in the inferior temporal cortex –BA20. 862 (Youngest-old (60–86 y.o.)); 87+ (Oldest-old (87–103 y.o.)); MD- mild dementia (CDR 0.5–1); SD-severe dementia
(CDR 4–5).
doi:10.1371/journal.pone.0007642.t001
Figure 1. Numbers of probe sets of differentially expressed
genes in cognitively impaired groups of two median split age
cohorts compared to corresponding age matching controls.
YO- young-old (#86 y.o.); OO –oldest-old ($87 y.o.); MD (CDRs 0.5–1)
and SD (CDRs 4–5). Overlapping regions include common number of
probe sets. Number in the center outside of all terms indicates probe
sets common across all of the tested groups.
doi:10.1371/journal.pone.0007642.g001
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Gene ontology classification of these common probe sets from two
age categories (Table 4), additionally, confirmed distinctive sets of
genes involved in different biological processes in the youngest-old
versus oldest-old groups.
The same canonical immune function pathways that were identified
in the oldest-old individuals with mild dementia (Table 3) were affected
in the oldest-old cognitively intact persons (Table 5), but in opposite
directions (see above). Additional pathways identified were two
metabolic pathways: tyrosine and pyrimidine metabolism and
glucocorticoid signaling, pathway frequently implicated in brain aging.
The majority of the 75 probe sets (Fig. 2) that were differentially
expressed in the brain of cognitively intact and cognitively impaired
oldest-old, relative to cognitively intact young-old persons, were
related to immune response pathways (Table 5). Table 6 lists 37
genes after removal of redundant probes and genes of unknown
function from the 75 probe sets differentially expressed in the brain
of cognitively intact oldest-old individuals. These genes showed
strong upregulation in cognitively intact oldest-old persons relative
to young-old controls (Table 6 and Fig. S1). The vast majority of
these genes were profoundly downregulated in cognitively impaired
oldest-old persons (Table 6 and Fig. S1).
Comparison of microarray data for two age categories
using different normalization algorithms and different
microarray platforms
The GeneChip U133AB platform data described above was
normalized by MAS5. To further validate the microarray findings
we re-analyzed the U133AB array raw dataset using a different
normalization algorithm and performed microarrays of the same
Table 2. Canonical pathways affected in cognitively impaired youngest-old (#86 y.o.).
Pathway Name -Log(P-value) MD Ratio MD -Log(P-value) SD Ratio SD
GABA Receptor Signaling 5.09 1.32E-01 7.00 2.64 E-01
Glutamate Receptor Signaling 3.44 8.96E-02 2.31 1.34E-01
IGF-1 Signaling 3.21 7.61E-02 1.56 1.09E-01
Nitric Oxide Signaling in the Cardiovascular System 2.98 7.06E-02 2.21 1.18E-01
Synaptic Long Term Potentiation 2.73 6.31E-02 3.52 1.44E-01
Huntington’s Disease Signaling 2.52 4.31E-02 4.47 1.21E-01
Neuregulin Signaling 2.50 6.59E-02 ns ns
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 2.35 9.30E-02 ns ns
NF-kB Signaling 1.99 4.90E-02 ns ns
VEGF Signaling 1.88 5.43E-02 ns ns
Amyotrophic Lateral Sclerosis Signaling 1.84 4.85E-02 1.64 1.07E-01
Glutamate Metabolism 1.83 3.85E-02 ns ns
PPAR Signaling 1.82 5.26E-02 ns ns
Glucocorticoid Receptor Signaling 1.78 3.40E-02 ns ns
PI3K/AKT Signaling 1.74 3.98E-02 ns ns
GM-CSF Signaling 1.72 6.45E-02 ns ns
Xenobiotic Metabolism Signaling 1.68 3.60E-02 ns ns
Hypoxia Signaling in the Cardiovascular System 1.63 5.63E-02 ns ns
Synaptic Long Term Depression 1.61 3.68E-02 ns ns
Parkinson’s Signaling 1.57 1.18E-01 1.99 2.35E-01
NRF2-mediated Oxidative Stress Response 1.54 3.89E-02 ns ns
ERK/MAPK Signaling 1.52 3.54E-02 1.33 8.41E-02
PDGF Signaling 1.52 5.41E-02 ns ns
Cardiac b-adrenergic Signaling 1.49 3.85E-02 1.39 8.46E-02
G-Protein Coupled Receptor Signaling 1.39 3.52E-02 1.59 9.05E-02
Oxidative Phosphorylation ns ns 4.28 1.20E-01
Calcium Signaling ns ns 3.53 1.08E-01
cAMP-mediated Signaling ns ns 2.57 1.13E-01
Axonal Guidance Signaling ns ns 2.50 8.53E-02
Chemokine Signaling ns ns 2.04 1.33E-01
Actin Cytoskeleton Signaling ns ns 1.85 8.61E-02
Mitochondrial Dysfunction ns ns 1.45 7.88E-02
Leukocyte Extravasation Signaling ns ns 1.40 8.51E-02
{Fischer’s exact test was used to calculate p-values; the ratios are between the numbers of genes from the dataset that mapped to the pathway to the total numbers of
genes in the canonical pathway. MD = CDRs 0.5–1; SD = CDRs 4–5; ns- Non significant. Pathways are sorted in descending order based on significance for MD group.
Common pathways between the two young-old and oldest-old dementia groups are in bold font.
doi:10.1371/journal.pone.0007642.t002
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RMA normalization of the raw U133AB microarray data with
subsequent CGEM based differential gene expression discovery
using filtering condition similar to the MAS5 based analyses
showed that although the results of the two analysis procedures
differed with respect to the absolute number of differentially
expressed genes identified (Table 7), the correlations between the
two methods (r=0.98, p=0.003 for the numbers of differentially
expressed genes) remained very high. Additionally, comparison of
the MAS 5.0 normalization of U133AB array dataset with MAS
5.0 normalized values from the U133 Plus2 platform, also showed
strong significant correlations between two datasets (r=0.89,
p=0.04 for numbers of differentially expressed genes). Further-
more, pathway analysis indicated that affected genes were
represented by the same set of pathways associated with immune
responses irrespective of MAS5 vs. RMA analysis and U133AB or
U133 Plus2 array platforms (Table 8). The top six affected
pathways were common to the U133 Plus2 and the U133AB
datasets. The rest of the pathways identified by the U133 Plus2
platform expanded the number of previously detected signaling
pathways associated with immune function considerably.
Acute phase response, which includes IL-6 signaling was among
those affected in both microarray datasets in cognitively normal
(CDR0) and severely cognitively impaired (CDR4–5) oldest-old
subjects.Comparison ofthegenesinvolved inIL-6 signaling showed
that more than half of the genes identified in U133Plus2 datasets
were also detected as affected in U133AB datasets (Table 9). As
evident from the high correlations described above, the direction-
ality and magnitude of changes for those genes were very similar in
both microarray platforms and comparison groups. Higher
representation of differentially expressed genes in U133Plus2
dataset vs. those detected by U133AB can be explained, at least
in part, by the fact that the Plus2 chip contains 10,000 more probe
sets than the older U133AB chip as well as an improved detection
sensitivity limit over the older version of the chip.
Quantitative PCR validation of microarray gene
expression findings
Microarray findings indicated that abnormal expression of
antigen presentation, complement and inflammatory response
genes was most closely associated with dementia and its
progression in the oldest-old. We performed independent qPCR
analysis of a small subset of 8 genes that includes CD74, HLA-
DPA1, C3, LY96/MD-2, CX3CR1, TYROBP/DAP12, C1QC
and ITGB2 in a study of 4 groups (Table 1; young-old CDR 0;
young-old MD, oldest-old CDR 0; oldest-old MD) in the in-
ferior temporal gyrus (BA20). These immune-related genes were
selected for replication because they met high stringency filtering
conditions (fold change $1.7; p(t-test),0.001) in both MAS5 and
RMA normalization algorithms in cognitively normal oldest-old
individuals relative to the cognitively intact young-old donors in
the microarray analysis. The results of this study are shown in
Figure 3 and support the microarray findings by implicating the
significantly increased expression of five genes: CD74, HLA-
DPA1, C3, C1QC and LY96 (Table 9. All ps#0.013) in the
temporal cortex of cognitively normal oldest-old individuals
relative to the cognitively intact young-old donors. It is important
to note that the microarray analyses were based on global
changes across all brain regions examined, it is therefore not
surprising that only 5 of 8 transcripts evidenced differential
expression in the one brain region studied by qPCR. Further-
more, the expression of all eight tested genes was significantly
downregulated in cognitively impaired oldest-old individuals with
MD (Table 9) relative to age matched cognitively intact donors.
The expression of these genes was persistently downregulated in
oldest-old individuals (Table 9) relative to age-matched cogni-
tively intact donors, although only four: HLA-DPA1, LY96,
CX3CR1 and ITGB2 reached conventional level of significance
(p#0.05). In contrast, in young-old individuals with dementia
only two of these immune-associated genes were statistically
significantly changed, CD74 and LY96, and consistent with the
microarray findings and in contrast to oldest-old persons, their
expression was upregulated relative to cognitively intact young-
old individuals.
These results validate the microarray findings which showed
increased expression of immune/inflammatory genes in the
brains of cognitively intact oldest-old persons relative to
cognitively intact young-old perso n sa n dd e c r e a s e si nc o g n i t i v e l y
compromised oldest-old persons relative to cognitively intact
oldest-old controls.
Table 3. Canonical pathways affected in cognitively impaired oldest-old ($87 y.o.).
Pathway Name -Log(P-value) MD Ratio MD -Log(P-value) SD Ratio SD
Antigen Presentation Pathway 7.11 3.33E-01 1.40 2.82E-01
Complement System 3.63 1.67E-01 ns ns
Natural Killer Cell Signaling 2.31 4.55E-02 ns ns
Protein Ubiquitination Pathway 1.98 4.93E-02 ns ns
Acute Phase Response Signaling 1.69 4.07E-02 ns ns
Interferon Signaling 1.68 1.38E-01 ns ns
GM-CSF Signaling 1.61 8.06E-02 ns ns
Fc Epsilon RI Signaling 1.45 4.00E-02 ns ns
Methane Metabolism 1.40 3.08E-02 ns ns
IL-4 Signaling 1.36 5.88E-02 ns ns
Oxidative Phosphorylation ns ns 2.39 2.15E-01
Synaptic Long Term Potentiation ns ns 1.32 1.62E-01
{Fischer’s exact test was used to calculate p-values; the ratios are between the numbers of genes from the dataset that mapped to the pathway to the total numbers of
genes in the canonical pathway. ns- Non significant. Common pathways between the two young-old and oldest-old dementia groups are in bold font.
doi:10.1371/journal.pone.0007642.t003
Brain Immunity and Dementia
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associated proteins in young-old and oldest-old persons
with and without dementia
Three of the most affected immune genes in the oldest-old:
CX3CR1, HLA-DPA1 and CD74; were selected to assess whether
their protein levels were similarly affected as their gene expression
in the inferior temporal cortex. Figure 4 shows the results of
quantitative Western blot analyses (Fig. S2 and Fig. S3) of the
microglia-associated chemokine-fractalkine receptor CX3CR1
[42] and HLA-DPA1 (major histocompatibility complex, class II,
DP alpha1). CX3CR1 protein levels were significantly increased in
young-old persons with SD (CDR4–5, p=0.019), but significantly
decreased (p=0.028) in the oldest-old SD persons. Although in
this limited sample the increase in the level of CX3CR1 protein in
cognitively intact oldest-old persons did not reach statistical
significance, its levels were nominally elevated in the inferior
temporal cortex. HLA-DPA1 protein levels were significantly
increased in young-old persons with SD (p=0.052) and in
cognitively intact oldest-old individuals (p=0.011), and showed a
tendency to decrease in the oldest-old SD patients. Thus, the
changes in protein expression corroborate the same pattern of
gene expression found in the microarray and qPCR studies.
Figure 5 shows the results of quantitative Western blot analyses
of the invariant gamma chain of MHC class II protein CD74
antigen (Fig. S4), which acts both as a chaperone for MHC class II
Table 4. GO biological processes categories of common
genes (Fig. 2) in youngest-old (#86 y.o.) and in oldest-old
($87 y.o.) persons.
GO ID GO NAME/#86y.o. (65 genes)
GO:0006811 ion transport
GO:0007268 synaptic transmission
GO:0019226 transmission of nerve impulse
GO:0007267 cell-cell signaling
GO:0050877 neurological system process
GO:0007186 G-protein coupled receptor protein signaling pathway
GO:0016192 vesicle-mediated transport
GO:0007010 cytoskeleton organization and biogenesis
GO:0042221 response to chemical stimulus
GO ID GO NAME/$87y.o. (75 genes)
GO:0016064 immunoglobulin mediated immune response
GO:0006959 humoral immune response
GO:0002252 immune effector process
GO:0042221 response to chemical stimulus
GO:0019883 antigen processing and presentation of endogenous antigen
GO:0006954 inflammatory response
GO:0019724 B cell mediated immunity
GO:0002541 activation of plasma proteins during acute inflammatory
response
GO:0051239 regulation of multicellular organismal process
doi:10.1371/journal.pone.0007642.t004
Table 5. Canonical pathways affected in cognitively intact
oldest-old ($87 y.o.) compared to cognitively intact
youngest-old (#86 y.o.).
Pathway Name -Log(P-value) Ratio
Antigen Presentation Pathway 6.76 4.36E-01
IL-4 Signaling 3.05 1.47E-01
Natural Killer Cell Signaling 3.05 1.00E-01
Complement System 2.33 1.11E-01
Acute Phase Response Signaling 2.21 7.56E-02
Tyrosine Metabolism 1.90 3.24E-02
Fc Epsilon RI Signaling 1.72 9.00E-02
Pyrimidine Metabolism 1.68 3.10E-02
Glucocorticoid Receptor Signaling 1.39 6.04E-02
{Fischer’s exact test was used to calculate p-values; the ratios are between the
numbers of genes from the dataset that mapped to the pathway to the total
numbers of genes in the canonical pathway. Immune-related pathways are in
bold font.
doi:10.1371/journal.pone.0007642.t005
Figure 2. Numbers of common probe sets in differentially
expressed genes between two age distinct cognitively intact
subjects (CDR0) compared to cognitively impaired groups for
each age cohorts. A. Venn diagram represents young-old cohort (YO;
#86 y.o.). B. Venn diagram represents oldest-old cohort (OO; $87 y.o.).
doi:10.1371/journal.pone.0007642.g002
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inhibitory factor (MIF). Western blotting with CD74 monoclonal
antibody recognizing the cytoplasmic tail detected multiple bands
ranging from 11 to 72kD with the main bands corresponding to
MWs: ,35/33, 41 and 11 kD. CD74- 33/35kD (Fig. 5A) as well
as total CD74 (data not shown) showed a tendency to increase in
patients with severe dementia in both age categories. In contrast to
35/33kD CD74, a small molecular size band (,11kD), corre-
sponding to the intracellular cleaved cytoplasmic domain of CD74
[43] that can function as an activator of NF-kB transcription factor
and B-cells enriched co-activator-TAF(II)105, showed the same
pattern of changes as CX3CR1 and HLA-DPA1 (Fig. 5B).
These results supported the observation that the expression of
genes and proteins associated with the inflammatory/immune
system is i) significantly increased in cognitively intact oldest-old
persons relative to cognitively intact young-old persons; and ii)
Table 6. Significantly affected genes (p,0.05) in the oldest-old ($87 y.o.) cohort in comparison to cognitively intact youngest-old
(#86 y.o.) subjects.
Gene Name Symbol CDR 0 MD (CDR0.5–1) SD (CDR 4–5)
Major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 10.35 27.03 25.67
TYRO protein tyrosine kinase binding protein (DAP12) TYROBP 9.83 25.83 24.38
Complement component 3 C3 9.81 25.31 24.39
Major histocompatibility complex, class II, DR beta 1 HLA-DRB1, 3 8.59 25.48 23.97
Glycoprotein (transmembrane) nmb GPNMB 8.57 26.96 24.89
Complement component 1, q subcomponent, C chain C1QC 8.06 25.65 25.77
CD74 molecule, major histocompatibility complex, class II
invariant chain
CD74 7.85 25.6 23.86
Complement component 4A (Rodgers blood group) C4A, C4B 7.49 25.76 22.94
Major histocompatibility complex, class I, B HLA-B 7.15 25.21 25.46
Lectin, galactoside-binding, soluble, 1 (galectin 1) LGALS1 7.11 24.4 24.03
Major histocompatibility complex, class II, DR beta 1, 3–5 HLA-DRB1, 3–5 6.9 24.72 23.68
Major histocompatibility complex, class I, A HLA-A 6.83 25.56 25.78
Lymphocyte antigen 96 (MD-2) LY96 6.81 25.1 23.39
Retinoic acid receptor responder (tazarotene induced) 3 RARRES3 6.55 25.23 25.2
Major histocompatibility complex, class I, F HLA-F 6.34 24.65 24.59
Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 SERPING1 6.01 24.78 23.79
Chemokine (C-C motif) receptor 1 CCR1 5.93 24.47 23.93
Fc fragment of IgE, high affinity I, receptor for; gamma
polypeptide
FCER1G 5.71 24.24 23.4
HLA-G histocompatibility antigen, class I, G HLA-G 5.67 24.17 24.15
Major histocompatibility complex, class I, E HLA-E 4.91 23.65 24.06
Proteasome (prosome, macropain) subunit, beta type, 9 PSMB9 4.84 24.32 23.37
Lectin, galactoside-binding, soluble, 3 binding protein LGALS3BP 4.27 24.02 24.32
Proteasome activator subunit 2 (PA28 beta) PSME2 4.23 24.39 25.97
Interferon-induced protein 44 IFI44 4.19 24.85 24.25
Interferon induced transmembrane protein 1 (9–27) IFITM1 4.15 23.41 24.29
Serpin peptidase inhibitor, clade A (antitrypsin), member 3 SERPINA3 4.09 22.37 23.57
Tumor necrosis factor superfamily, member 13b TNFSF13B 4.07 23.93 24.46
Interferon-stimulated transcription factor 3, gamma 48kDa ISGF3G 3.84 24.25 24.26
Dystrobrevin, alpha DTNA 3.84 23.3 24.09
Hepcidin antimicrobial peptide HAMP 3.74 23.43 23.96
Secreted phosphoprotein 1 (osteopontin) SPP1 3.5 23.18 23.24
Vascular endothelial growth factor VEGF 3.11 23.01 22.28
Myxovirus resistance 1, interferon-inducible protein p78 MX1 2.83 23.6 23.15
Interferon-induced protein with tetratricopeptide repeats 3 IFIT3 2.42 24.93 24.78
Homeodomain interacting protein kinase 2 HIPK2 22.81 2.7 5.82
Multiple C2 domains, transmembrane 1 MCTP1 24.54 6.38 3.24
RUN and FYVE domain containing 2 RUFY2 29.07 9.76 8.37
{Redundant probes and unknown hypothetical proteins were removed. Genes are ranked using t-scores which were calculated by comparison with cognitively intact
youngest-old (,86) subjects across of the 15 brain regions using Contrast analysis (GX
TM Explorer, Gene Logic Inc.). Genes are arranged in order of decreasing t-scores
in CDR0 subjects. Immune-response genes are in bold.
doi:10.1371/journal.pone.0007642.t006
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cognitively intact oldest-old controls.
Discussion
The notion that AD with its hallmark neuritic plaque,
neurofibrillary tangle, and neurochemical system lesions is the
preeminent cause of dementia in the elderly as been among the
cornerstones of our conceptualizations of aging and dementia.
This understanding has been supported by the nearly ubiquitous
presence of AD pathological changes in age-related dementia as
well as the near exponential increase of AD prevalence after 65
years of age. Increasingly, neuropathological and neuroanatomical
studies (see introduction) have called this long-held tenet into
question by suggesting that the neuropathological and neurobio-
logical substrates of dementia can vary considerably between
younger old vs. oldest-old persons. These latter observations have
become increasingly salient with the knowledge that the oldest-old
represent the fastest growing segment of the aging population with
their numbers expected to reach above 19 million by the year
2050. The current study sought to identify some of the molecular
biological substrates of dementia in the oldest-old and to
determine how the neurobiology of dementia may change with
increasing age. We examined gene expression changes across
multiple brain regions in oldest-old individuals with or without
cognitive impairment and compare them to those in more
conventionally studied young-old persons. Our findings suggest
that immune/inflammation-associated systems of the brain occupy
a central role not only in the processes related to cognitive
impairment in the oldest-old, but also with the preservation of
cognitive function and healthy aging in extreme old-age. The
results reported here also support the emerging neuropathology
literature in the oldest-old population by suggesting that often the
neurobiological substrates of dementia in the oldest-old may be
qualitatively different than those prevalent in younger old persons.
Analysis of a large microarray dataset identified a lack of
significant overlap in differentially expressed gene sets associated
with dementia in young-old vs. oldest-old persons. The top of the
list of significantly altered signaling pathways in young-old persons
with dementia was well represented with pathways associated with
neurotransmission and synaptic function: GABA and glutamate
receptor signaling, synaptic LTP and neural development,
including genes participating in neuregulin, IGF1, VEGF
signaling, axonal guidance and calcium signaling. As expected
Table 7. Number of significantly affected probe sets in U133AB and U133Plus2 microarray chips using MAS5 and RMA-CGEM –
based analysis in two median age split cohorts.
Microarray Normalization/Platform
CDR0.5–1 862 vs
CDR0 862
CDR 4–5 862 vs
CDR0 862
CDR0 87+ vs CDR0
862
CDR0.5–1 87+ vs
CDR0 87+
CDR 4–5 87+ vs CDR0
87+
MAS5/U133AB 262 1071 332 132 1091
RMA-CGEM/U133AB 305 810 313 207 1023
MAS5/U133 Plus2 482 1875 979 382 1115
{Filtering conditions were as following: MAS5-based: Fold change $1.3; p-val (t-test) #0.05; presence .70%; RMA-CGEM: Fold change $1.3; p-val (ANOVA) #0.05;
presence .70%.
doi:10.1371/journal.pone.0007642.t007
Table 8. Comparison of the pathways affected in cognitively normal oldest-old compared to cognitively normal youngest-old
analyzed on two different microarrays (U133AB and U133Plus2).
Pathway Name
-Log(P-value)
U133AB Ratio U133AB
-Log(P-value)
U133Plus2 Ratio U133Plus2
Antigen Presentation Pathway 6.76 4.36E-01 9.45 4.36E-01
IL-4 Signaling 3.05 1.47E-01 4.38 2.27E-01
Natural Killer Cell Signaling 3.05 1.00E-01 4.38 2.27E-01
Complement System 2.33 1.11E-01 2.75 2.78E-01
Acute Phase Response Signaling 2.21 7.56E-02 2.98 1.82E-01
Fc Epsilon RI Signaling 1.72 9.00E-02 2.95 2.08E-01
Synaptic Long Term Potentiation ns ns 9.65 3.12E-01
Fcc Receptor-mediated Phagocytosis in Macrophages ns ns 7.68 2.88E-01
Interferon Signaling ns ns 4.32 3.79E-01
GM-CSF Signaling ns ns 3.90 2.74E-01
Chemokine Signaling ns ns 3.89 2.53E-01
IL-8 Signaling ns ns 3.63 1.86E-01
IL-4 Signaling ns ns 3.51 2.43E-01
B Cell Receptor Signaling ns ns 3.35 1.92E-01
{Fischer’s exact test was used to calculate p-values; the ratios are between the numbers of genes from the dataset that mapped to the pathway to the total numbers of
genes in the canonical pathway. Common pathways between two microarray platforms are in bold font.
doi:10.1371/journal.pone.0007642.t008
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Gene Symbol
CDR0 87+ vs CDR0
862 FC Ratio (p-value)
MD 87+ vs CDR0 87+ FC
Ratio (p-value)
SD 87+ vs CDR0
87+ FC Ratio (p-value)
MD 862 vs CDR0
862 FC Ratio (p-value)
SD 862 vs CDR0 862FC
Ratio (p-value)
CD74 2.28 (0.001) 21.77 (0.002) 21.17 (ns) 1.59 (0.027) 1.72 (0.031)
LY96/MD-2 2.26 (4-E4) 21.76 (9-E5) 21.24 (0.04) 1.45 (ns) 1.72 (0.048)
HLA-DPA1 1.65 (2-E4) 21.53 (1-E4) 21.26 (0.015) 1.09 (ns) 1.10 (ns)
C1QC 1.45 (0.027) 21.52 (0.012) 21.20 (ns) 1.15 (ns) 1.22 (ns)
C3 1.38 (0.013) 21.76 (7-E5) 21.13 (ns) 21.21 (ns) 21.12 (ns)
TYROBP/DAP12 1.25 (ns) 21.48 (0.002) 21.14 (ns) 1.02 (ns) 1.07 (ns)
ITGB2 21.20 (ns) 22.07 (1-E4) 21.88 (0.002) 21.84 (ns) 21.83 (ns)
CX3CR1 1.16 (ns) 21.74 (0.001) 21.41 (0.049) 21.05 (ns) 21.38 (ns)
Tissue samples from BA20 were analyzed by qPCR. FC Ratio-fold change ratios represent the ratio of means for each gene normalized to the geometric means of four
housekeeping genes between controls and cognitively impaired patients. Significantly changed genes (p,0.05) are highlighted in bold. ns- non-significant.
doi:10.1371/journal.pone.0007642.t009
Figure 3. Relative mRNA expression of the immune system related genes in the inferior temporal cortex (BA20) of persons with
dementia and cognitively normal (CDR0) individuals measured by qPCR. Subject characteristics are shown in Table 1. Group definitions are
as indicated on the figure (MD = CDRs 0.5–1; SD = CDRs 4–5). Data is expressed as geometric means 6 SEM of individual expression values
normalized to the four housekeeping genes: B2M, GUSB, PPIA and RPLP0 as described in Methods. Significance is indicated by the comparison lines.
Fold change values and p-values are shown in Table 9.
doi:10.1371/journal.pone.0007642.g003
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these pathways were downregulated in cognitively impaired
individuals. Other affected pathways included networks of genes
previously implicated in brain aging: IGF1, glucocorticoid
receptor, nitric oxide and NF-kB signaling, cell cycle regulation,
oxidative stress response, and pathways associated with neurode-
generation: hypoxia, Huntington’s and Parkinson’s diseases and
amyotrophic lateral sclerosis signaling. These data are consistent
with previous genome-wide gene expression studies of different
brain regions from persons with dementia and AD with designs
that did not distinguish between young-old and oldest-old cases
and utilized brain specimens from persons the majority of whom
fall within the young-old age range of the current study [37–
40,44].
In contrast to young-old persons, oldest-old subjects with mild
dementia evidenced predominant abnormalities in pathways
associated with the immune response system including antigen
presentation, classic complement system, and oxidative phosphor-
ylation. Also in contrast to young-old subjects, oldest-old subjects
with dementia show under representation of pathways and gene
ontology (GO) categories related to neuronal function and were
limited only to LTP. These results are in agreement with data
derived from neuropathology studies indicating that oldest-old
individuals with AD display striking resistance to at least some
neurodegenerative processes and only mild neuronal loss in the
hippocampus [13], underscoring the limits of neuropathological
‘‘lesion’’ hypotheses of AD and dementia progression in this
particular age group [28,45].
We performed analyses of the microarray data sets to address
the question of the expression of genes that are important to both
healthy aging, i.e., as people age from young-old to oldest-old
without dementia, and to dementia irrespective of age. The
expression of 65–75 transcripts was changed in all 5 groups
(cognitively intact oldest-old; cognitively compromised young-old
(mild and severe dementia) and cognitively compromised oldest-
old (mild and severe dementia)) relative to the cognitively intact
young-old index group (Fig. 2, Table 6). The vast majority of these
genes were related to immune function. Interestingly, while the
expression of some of these genes was increased in young-old
persons with dementia, consistent with the previous reports on AD
[46–52], the expression of the majority of immune response genes
was down-regulated in the studied brain regions of cognitively
impaired oldest-old persons. Furthermore, the expression of these
immune-system related genes was increased in the brains of
cognitively intact oldest-old persons. Interestingly, the upregula-
Figure 4. Relative abundance of CX3CR1 (A) and HLA-DPA1 (B)
proteins in the inferior temporal cortex –BA20 of patients with
SD (CDR4–5) and cognitively normal (CDR0) individuals. Protein
levels of CX3CR1 and HLA-DPA1 were measured by Western Blot (Suppl.
Fig. 2 and 3). Data expressed as means 6 SEM of ODs normalized to the
generic sample – ‘‘calibrator’’ and endogenous control - TUBB protein
(N=9–10/group, see Table 1).
doi:10.1371/journal.pone.0007642.g004
Figure 5. Relative abundance of CD74 -35/33kD (A) and -11kD
(B) proteins in the inferior temporal cortex –BA20 of patients
with SD (CDR4–5) and cognitively normal (CDR0) individuals.
Protein levels of CD74 were measured by Western Blot (Suppl. Fig. 4).
Data expressed as means 6 SEM of ODs normalized to the generic
sample – ‘‘calibrator’’ and endogenous control - TUBB protein (N=9–
10/group, see Table 1).
doi:10.1371/journal.pone.0007642.g005
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noted in the oldest-old are similar to those of a recent microarray
study of gene expression across the lifespan in four brain regions
[35].
Nine genes, members of major histocompatibility complex
(MHC) classes I and II, were the most prevalent group among
differentially expressed genes in cognitively normal oldest-old
individuals. These molecules are central to antigen presentation
processes to T-cells suggesting the presence of antigen presenting
cells capable of initiating primary or secondary immune responses.
In the CNS, MHC class II immunoreactivity is abundantly
detected in activated microglia, in lymphocytes within the neuropil
and scarcely in astrocytes in sporadic AD, and is also constitutively
expressed by microglia in the white matter during normal aging
[53,54]. Increased expression of Toll-like receptor, TLR4 and
lysosomal associated membrane protein - LAMP2 in cognitively
normal oldest-old individuals detected in the microarray analyses
(data not shown) corroborate expression of MHC genes and
suggests activation of the initial steps in antigen processing and
presentation, such as acquisition of antigens and recruitment of
phagolysosomes necessary for proteolysis of antigenic peptides.
Whether upregulation of MHC class I and II genes in cognitively
normal oldest-old individuals is functionally associated with
antigen presentation or is involved in interactions between neural
and glial cells needs further investigation.
The CX3CR1, fractalkine receptor is expressed by a wide
spectrum of hemopoietic cells in the periphery. In the CNS,
CX3CR1 was first described on microglia [55] and later in
neurons [56]. Since fractalkine, the exclusive ligand for CX3CR1
is predominantly expressed by neurons the factalkine-CX3CR1
complex may be central for neuron-microglia communication
[57]. It has been suggested that the expression of CX3CR1 has
beneficial neuroprotective and neuronal survival consequences in
animal models of systemic inflammation, Parkinson disease and
amyotrophic lateral sclerosis [58]. These beneficial effects may
result from fractalkine-CX3CR1 elicited signaling leading to the
suppression of pro-inflammatory cytokines and ROS production
[59,60].
DAP12/TYROBP and LY96 were among the genes whose
expression was significantly affected in successful aging and in
dementia in oldest-old persons, albeit in different directions.
DAP12/TYROBP is associated with a large family of receptors
including those that recognize MHC class I molecules in
hematopoietic cells: dendritic cells, monocytes, macrophages,
natural killer cells, and some B and T cells. The importance of
DAP12 in brain function is demonstrated by the fact that loss-of-
function mutation of DAP12 is associated with a rare presenile
dementia known as Nasu-Hakola disease [61]. LY96/MD-2 is a
component of a tri-molecular complex consisting of TLR4, LY96
and CD14 which is a critical effector of microglial activation. The
potential importance of this complex to AD-associated dementia is
suggested by in vitro experiments that have shown that
impairment of this complex inhibits microglial and monocytic
activation by aggregated Ab peptide [62].
Upregulation of two components of the classical complement
system - C3 and C1Q suggests initiation of the complement
cascade which ultimately leads to formation of the membrane
attack complex (C5b-9) that targets affected cells for lysis [63].
Activation of the classic and alternative complement pathways
during progression of AD has been detected in numerous studies
(for review see [64]) and may mediate, at least in part,
inflammation and neurodegeneration in AD. The complement
and innate immune system, however, may have dual, beneficial
and harmful, effect on CNS [47,64]. Harmful effect, when it
causes extensive tissue damage, or protective, when it binds and
removes toxic cellular debris, protein aggregates and/or patho-
gens. To protect cells against potentially harmful action of
activated complement complexes cells are equipped with comple-
ment inhibitors, such as SERPING1, a C1 inhibitor, which
belongs to a large family of serine protease inhibitors (serpins) and
inhibits the proteolytic activity of C1 subcomponents C1r and C1s
[65]. Consistent with its protective function, gene expression of
SERPING1 was increased in cognitively normal oldest-old
subjects and downregulated in demented subjects from the same
age category (Table 5).
The source of the immune related gene expression changes in
oldest-old persons is not directly discernable from the current data
set. The lack of detectable signals for T-cell receptors, which are
central for antigen presentation to T cells in our microarrays,
refutes the presence of infiltrating CNS peripheral T cells.
Immune related gene expression changes could be attributable
to expression changes in microglia, astrocytes, neurons or vascular
elements. Only future detailed immunohistochemical studies can
address this question fully. However, we note that there were no
differences between levels of conventionally accepted markers for
astrocytes (GFAP- glial fibrillary acidic protein, PEA15-phospho-
protein enriched in astrocytes,15kD, ApoE and aquaporin 4),
oligodendrocytes (MBP, MAG, CNP, SOX10, OLIG2 and PLP),
neurons (ENO2, NEFL and NEFH) or microglial (CD68, CD11
and MMP12) markers between young-old and oldest-old individ-
uals.
The abundant expression level of four identified immune-
related genes (HLA-DPA1, CD74, CX3CR1 and C3), their
significant correlations with L-ferritin (r$0.7; p,0.01), a gene
predominantly expressed in microglia [66] and lack of significant
positive correlations with neuronal, oligodendrocytes and astro-
cytes markers, suggests an association of both cognitive health and
compromise with CNS resident microglial cells, rather than with
infiltrating peripheral hemopoietic cells. In response to injury,
quiescent microglial cells with characteristics of immature myeloid
lineage cells, undergo rapid morphological and functional
transformation and acquire properties of mature myeloid cells,
including antigen presentation, matrix metalloproteinase produc-
tion and phagocytosis, as well as cytokine and growth factor
secretion. These properties of microglia may confer neuroprotec-
tive or neurotoxic effect to neural tissue. Several identified genes in
cognitively intact oldest-old subjects are known to encode proteins
capable of protecting against microglial neurotoxicity in animal
models. CX3CR1 null mice show more neuronal loss and cell-
autonomous microglial neurotoxicity than control mice[58] and
DAP12/TYROBP [67] or associated receptor TREM2 [68] null
mice show impaired phagocytic activity and enhanced inflamma-
tory gene expression that is manifested in adult onset dementing
leukoencephalopathy caused by loss of function mutations of
DAP12 or TREM2. Overall these observations suggest that
cognitively intact oldest-old subjects may have developed microg-
lial-mediated protection of neural cells against age–related
microglial neurotoxicity and/or accumulated neurotoxic mole-
cules, such as Ab.
These microarray, qPCR and protein expression results strongly
suggest that 1) the neurobiological substrates of dementia in
young-old individuals are not identical to the neurobiological
mechanisms that underlie dementia in oldest-old persons; 2) the
predominant genes whose expression is affected in demented
young-old persons comprise those associated with neurotransmis-
sion and synaptic function, whereas affected neurobiological
pathways in oldest-old demented persons are more likely to be
associated with immune/inflammatory responses of the CNS; and
Brain Immunity and Dementia
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old age, the oldest-old, express a select set of immune/
inflammatory genes at a higher level than young-old persons with
intact cognition. These analyses also support the neuropatholog-
ical study findings described above by suggesting that the
neurobiological processes that subserve the development and
progression of dementia in ‘‘conventional’’ young-old subjects
have features that are fundamentally different from those
associated with dementia in the oldest-old. One parsimonious
interpretation of the expression of immune system marker genes in
the oldest-old is that a robust immune system is essential for the
maintenance of cognitive health to very old age [35,69,70], and
that a failure of this system to respond to activating stimuli may
contribute to the development of dementia in the oldest-old.
Materials and Methods
Ethics Statement
Diagnostic and postmortem consent procedures were approved
by the institutional review boards of Mount Sinai Medical Center,
Jewish Home and Hospital and J.J. Peters VA Medical Center.
Consents for brain donation were obtained in writing from the
legal next of kin of all donors.
Sample Information and Preparation of Total RNA
Brain tissue specimens were derived from the Brain Bank of the
Department of Psychiatry of the Mount Sinai School of Medicine
(New York, NY)/J.J. Peters VA Medical Center (Bronx, NY). The
precise tissue handling procedures have been described in
detail.[14,15,31,71] Cerebral cortical regions (approximately
0.8–1 cm
3) limited to grey matter from the frontal cortex
(Brodmann areas BA: 8 (superior frontal gyrus), 10 (frontal pole),
44 (inferior frontal gyrus), 46 (dorsolateral prefrontal cortex), 4
(precentral/gigantopyramidal), anterior cingulate (ACG, BA: 24/
32 – at the level of the genu of the corpus callosum)), posterior
cingulate cortex (BA: 23/31 – at the level of the pulvinar), parietal
cortex (BA: 7 – superior parietal lobule), temporal cortex (BA: 20
(inferior temporal gyrus), 21 (middle temporal gyrus), 22 (superior
temporal gyrus), 36/28 (parahippocampal gyrus/entorhinal cor-
tex)), 38 (temporopolar) and occipital cortex (BA: 17 – primary
visual cortex) regions and from the hippocampus (at the level of
the red nucleus) were dissected from flash frozen coronal sections,
pulverized at 280uC and aliquoted. Aliquots (50 mg) from each
region were used for microarray gene expression analysis. RNA
isolation and preparation for the microarrays were as described
previously [72,73]. Similarly prepared aliquots from the BA20
(inferior temporal gyrus) were used in qPCR [74] and Western
blot analyses.
All subjects died of natural causes with no history of licit or illicit
drug abuse or neurological disease. Cognitively intact subjects
(CDR0) with no evidence of neurological or neuropsychiatric
diseases were matched with dementia subjects by age, postmortem
interval (PMI) and brain pH (Table 1). The predominant causes of
death were cardiovascular disease and myocardial infarction,
cancer, septicemia and bronchopneumonia. Brain specimens from
subjects who were comatose for more than 6 hours prior to death
were excluded from the current study.
Subject selection, cognitive assessment,
neuropathological assessment and group stratification
All subjects were evaluated in detail for cognitive status during
the last 6 months of life and the neuropathological assessment
procedures were as previously described [14,15,71]. Fifty-three
subjects were included in this postmortem study as the principal
cohort. The subjects were selected from a large group of study
participants who came to autopsy and had been residents of the
Jewish Home and Hospital (JHH) in Manhattan and the Bronx,
New York, other area nursing homes and assisted living facilities
and the community. The cohort of subjects included in the
microarray analysis was part of a larger clinical and epidemiologic
study of early AD that has been extensively described in previous
publications [31,75]. Exclusion criteria were: presence of neuro-
pathological lesions not associated with AD (including, but not
limited to, Pick’s disease, Lewy body inclusions, Parkinson’s
disease, stroke, multi-infarct dementia, and severe cerebrovascular
disease judged to be sufficient to affect cognitive function [76,77]),
coma .6 hours prior to death, seizures or fever (.39uC) during
the 24 hours prior to death, unnatural cause of death; and
comorbid psychiatric disease such as schizophrenia. The Clinical
Dementia Rating scale (CDR) [41] was used as the primary
measure of dementia severity. Subjects were rated by the CDR to
have no cognitive deficits (CDR=0), questionable dementia
(CDR=0.5) and mild dementia -MD (CDR=1.0) were combined
in a single group, and severe to terminal dementia (SD)
(CDR=4.0–5.0) were combined in a single group (Table 1). A
multi-step consensus-dependent approach was applied to the
assignment of CDR scores based on cognitive and functional status
during the last 6 months of life as described previously [14,15].
When available, longitudinal neuropsychological assessment
results were also considered in deriving the final consensus CDR
score.
Microarray Procedure and Data Analysis
Microarray analysis was performed using Affymetrix (Santa
Clara, CA) HG-U133AB set as well as HG-U133 Plus2
GeneChipH as described in the standard protocol outlined in the
GeneChipH Expression Analysis Technical Manual (Affymetrix
Inc., Santa Clara, CA) and reported previously [31,72,73]. Each
human sample RNA was processed and run on separate U133AB
chip sets and U133 Plus2 chips. Data were normalized using MAS
5.0 algorithms and analyzed using the GX
TM Explorer v.3.0
(Gene Logic Inc., Gaithersburg, MD) tools (expression, compar-
ative and contrast analysis) as described previously [72,73]. Each
individual microarray/sample-region (15 brain regions) was
treated as an individual sample, though comparison analysis and
t-score calculation were performed by brain region. Microarray
analysis of multiple brain regions was an advantage in our study
over single region comparison. As it has been reported previously
by our groups and others [31,78], the degree of gene expression
change in different cortical regions fluctuates and depends to a
significant degree on disease severity. Gene expression change was
considered to be significantly altered if the change in expression
met the following criteria of p,0.05 relative to the expression level
in the control group; fold change $1.3, present calls $70%. To
validate the results obtained by MAS 5.0 analysis the raw
microarray data from 2147 HG-U133A and B individual chips
were transformed and analyzed using GeneSpring GX 7.3.1
(Agilent Technologies/Silicon Genetics, Santa Clara, CA). Raw
data were pre-normalized with Robust Multi-Chip Average
(RMA) [79,80] with subsequent log transformation, normalization
to the 50
th percentile of all values per chip and median-centered
per gene using GeneSpring normalization. Statistical comparisons
were made using GeneSpring’s Cross Gene Error Model (CGEM),
based on the deviation from 1.0 algorithm. The following filtering
criteria were used in these GeneSpring/RMA/CGEM analyses:
expression level $1; single factor ANOVA with confidence
(p#0.05) and fold change ($1.4).[81] Genes accepted for
subsequent validation by qPCR were those that met the high
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and RMA based normalization of microarray analyses. Confir-
matory microarrays using the same samples were additionally
performed using newer version human genome arrays - Affymetrix
HG-U133 Plus 2. The same MAS5.0 normalization and analysis
procedures were applied to these datasets.
Ingenuity Pathway Analysis
Datasets containing identifiers for the genes expressed (presence
$80%) in the samples from the comparison analyses and
corresponding differential expression scores (fold change values,
t-scores and p-values) obtained from comparison analysis (MAS5.0
normalization, GX
TM Explorer v.3.0, Gene Logic Inc.) were
uploaded into the Ingenuity Pathway Analysis application.
Differentially regulated genes (p#0.05) were overlaid onto a
global molecular network in the Ingenuity Pathways Knowledge
Base (IngenuityH Systems, www.ingenuity.com) to identify biolog-
ical functions and canonical pathways. Ingenuity pathway analysis
algorithmically generates networks of genes based on their
connectivity. Fischer’s exact test was used to calculate a p-value
determining the probability that each biological function assigned
to that dataset, or the association between genes in the dataset and
the canonical pathway, was not due to chance alone. Significant
(ps,0.05) canonical pathways were additionally ranked according
to the ratios between the numbers of genes from the dataset that
mapped to the pathway to the total numbers of genes in the
canonical pathway. The scores for the networks were calculated
based on the number of network eligible genes and the size of the
network to approximate how relevant any particular network was
to the total list of eligible genes.
RT-qPCR
The mRNA levels of immune-related genes, which met
selection criteria of both MAS 5.0- and RMA-based microarray
analysis were measured by qPCR in a larger independent cohort
from BA20 (inferior temporal gyrus - Table 1) using TaqManH
MGB probes and primer sets (Applied Biosystems, Foster City,
CA).
For relative quantification of mRNA expression, relative values
of examined genes calculated using the standard curve method
were further normalized to geometric means (GMs) of endogenous
control-genes as described previously [82]. Four housekeeping
genes (GUSB, B2M, PPIA and RPLP0) were used as endogenous
controls for human postmortem studies in BA20 and tested for
the expression stability using geNorm (http://medgen.ugent.be/
,jvdesomp/genorm/).
Quantitative Western Blotting
Protein abundance was measured in the inferior temporal
cortex, BA20 (Table 1), from severe dementia (CDRs 4–5) and
CNT subjects (N=10/group) from two age categories previously
selected for microarray analysis using Western blotting.
Tissue specimens (50 mg sister aliquots to those used for qPCR)
were homogenized in Urea/Tris solution: 50 mM Tris/HCl
pH 7.4; 6 M Urea; 2% CHAPS containing 1 mM PMSF and
cocktails of proteinase/phosphatase inhibitors (Pierce Biotech Inc,
Rockford, IL). Total protein concentration in the tissue homog-
enates was determined with a CBQCA Quantitation Kit
(Molecular Probes Inc, Eugene, OR). Aliquot samples of 15 mg
of total protein in triplicates were loaded onto pre-cast 4–12%
Tris-glycine gel (Invitrogen, Carlsbad, CA) under reduced
conditions. A ‘‘standard-calibrator’’ (a mix of small aliquots of
tissue from all samples) was used as a calibrator between the gels
and run on each gel in triplicate. Blots were incubated with
antibodies: rabbit anti-human CX3C chemokine fractalkine
receptor 1, CX3CR1 (1:500 v/v) from LifeSpan Biosciences Inc.
(Seattle, WA); mouse anti-human HLA-DPA1 (1:100 v/v) from
Abnova (Walnut, CA); mouse mAb against human CD74 antigen
protein (1:1000 v/v), which recognizes cytoplasmic tail of CD74
(Cedarlane/StressMarq, Burlington, NC) and mouse anti-human
b tubulin (TUBB; 1:1000 v/v) – from Santa Cruz Biotech. Inc.
(Santa Cruz, CA) or rabbit anti-human TUBB (Novus Biologicals,
Littleton, CO). Electrophoresis, blotting, immunostaining, and
infra-red (IR) fluorescence detection (IRDye 680 or 800 Goat
Anti-appropriate species IgG, Li-Cor Biosciences, Lincoln, NE)
were performed under standard conditions. Multiplex western
blots were scanned on Odyssey Infrared Imaging System (Li-Cor
Biosciences, Lincoln, NE). The linearity of the dose responses for
the antibodies used was established in preliminary experiments.
Images were analyzed and quantitated with Odyssey software
ver.3 (Li-Cor Biosciences, Lincoln, NE). To account for gel to gel
variability, the relative expression value (REV) of analyzed
proteins in each sample was calculated as a ratio between the
averaged intensities of the band in the experimental sample and in
the ‘‘standard-calibrator’’. Finally, relative values for examined
proteins were normalized to endogenous control - TUBB.
Statistical Data Analysis
Multiple statistical procedures were employed for different
aspects of the study. Max t-scores, Pearson correlation coefficients
and corresponding p-values (ANOVA) [83,84] for each individual
transcript were calculated by the contrast analysis of MAS5.0
normalized microarray data using the GX
TM Explorer v.3.0 (Gene
Logic Inc., Gaithersburg, MD). T-scores were used as a
standardized measure of gene expression change for each
individual transcript across all of the analyzed brain regions and
described in detail previously [72,75]. Contrast analysis is an
extension of the fold change algorithm which takes in account
variability and estimates how well individual gene expression
patterns fit a specified model (the contrast pattern vector). The
contrast pattern vectors were set up in a way to outline the
increase of expression levels in tested sample set. Accordingly,
larger positive scores together with significant (p#0.01) and
Pearson correlation coefficients meant that the pattern of variation
of expression values between sample sets closely follows the pattern
represented by the contrast vectors, indicating upregulation of
gene expression. Large negative t-score values together with
significant (p#0.01) negative Pearson correlation coefficients
meant that the pattern of variation is the inverse to the pattern
represented by the contrast vectors, indicating downregulation of
gene expression. Finally, t-scores close to zero meant that the
gene’s expression pattern matches neither the contrast pattern nor
its inverse, or that the amount of variation between sample sets is
comparable to or smaller than the variation within sample sets.
Differences in expression between CNTs and different groups of
demented persons in the GeneSpring/RMA/CGEM analyses
were examined using a one-way analysis of variance (ANOVA)
with Benjamini and Hochberg multiple testing/false discovery rate
corrections.[81] A two-tailed Student’s t-test was used to compare
relative mRNA expression of analyzed genes in qPCR experi-
ments and relative abundance of proteins in Western blots.
Student’s t-test and correlation analyses were performed using
Statistica (release 6.0).
Supporting Information
Figure S1 Heat map of differentially expressed 75 common
probe sets in YO and OO cognitively intact (CDR0) groups and
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(Fig. 2) identified by comparison between cognitively intact
individuals YO (862) and OO (87+) cohort. CDR0 groups are
controls and SD group includes individuals with severe dementia
(CDR4–5). Individual intensities of differentially expressed probe-
sets from two brain regions: BAs 20 and 32. were standardized to
have a mean of 0 and standard deviation 1 by linear
transformation. Transformed data were ordered by the Cluster
software, v.3.0. Each row represents a single transcript. Column
sets represent comparison groups as indicated at the top of each
set. The color scale extends from 21.8 to +1.8. Red part of the
scale indicates positive values. Blue part of the scale indicates
negative values.
Found at: doi:10.1371/journal.pone.0007642.s001 (0.19 MB
DOC)
Figure S2 Western blots of CX3CR1 and beta tubulin -TUBB
in inferior temporal cortex (BA20). Signal for CX3CR1 appeared
as a doublet/triplet band ,50kD (under reducing conditions).
Extended boiling (up to 5 hours) of protein extract in the presence
of 2-mercaptoethanol eliminate these bands, and CX3CR1
appears as a single band ,50kD. Optical density was measured
for all of the bands.
Found at: doi:10.1371/journal.pone.0007642.s002 (0.45 MB TIF)
Figure S3 Western blots of HLA-DPA1 and beta tubulin -
TUBB in inferior temporal cortex (BA20). Signal for HLA-DPA1
appeared as a doublet band ,29kD (under reducing conditions).
Extended boiling (up to 5 hours) of protein extract in the presence
of 2-mercaptoethanol eliminate doublet, and HLA-DPA1 appears
as a single band ,29kD. Optical density was measured for all of
the bands.
Found at: doi:10.1371/journal.pone.0007642.s003 (0.14 MB TIF)
Figure S4 Western blots of CD74 and beta tubulin -TUBB in
inferior temporal cortex (BA20). Signals for HLA-DPA1 appeared
in multiple bands ranging from 11 to 72kD with the main bands
corresponding to MWs: doublet 33/35, 41 and 11 kD (under
reducing conditions).
Found at: doi:10.1371/journal.pone.0007642.s004 (0.73 MB TIF)
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